|CTI BioPharma Corp.|
3101 Western Avenue
United States - Map
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA for the development and commercialization of pacritinib for use in oncology and other therapeutic areas. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
|CTI BioPharma Corp.’s ISS Governance QuickScore as of Mar 1, 2015 is 10. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. James A. Bianco M.D.,
Principal Founder, Chief Exec. Officer, Pres, Exec. Director, Member of Scientific Advisory Board and Member of Exec. Committee
|Dr. Jack W. Singer M.D.,
Co-Founder, Chief Compliance Officer, Interim Chief Medical Officer, Exec. VP of Global Medical Affairs & Translational Medicine, Exec. Director and Member of Scientific Advisory Board
|Mr. Louis A. Bianco CPA,
Co-Founder, Principal Financial Officer, Principal Accounting Officer, Chief Governance Officer, Exec. VP of Fin. & Admin. and Sec.
|Dr. Matthew J. Plunkett Ph.D.,
Exec. VP of Corp. Devel.
|Ms. Monique M. Greer Sr.,
Sr. VP of Corp. Communications and Investor Relations
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|